Celgene Corporation (NASDAQ:CELG) Stake Held by Yorktown Management & Research Co Inc

Yorktown Management & Research Co Inc continued to hold its position in Celgene Corporation (NASDAQ:CELG) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,100 shares of the biopharmaceutical company’s stock at the end of the first quarter. Yorktown Management & Research Co Inc’s holdings in Celgene Corporation were worth $261,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Diversified Trust Co boosted its stake in Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 9 shares during the period. Quadrant Capital Group LLC boosted its stake in Celgene Corporation by 0.8% in the first quarter. Quadrant Capital Group LLC now owns 4,073 shares of the biopharmaceutical company’s stock valued at $492,000 after buying an additional 34 shares during the period. Cadence Bank NA boosted its stake in Celgene Corporation by 0.6% in the first quarter. Cadence Bank NA now owns 7,496 shares of the biopharmaceutical company’s stock valued at $933,000 after buying an additional 45 shares during the period. Washington Trust Bank boosted its stake in Celgene Corporation by 1.3% in the first quarter. Washington Trust Bank now owns 3,613 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 46 shares during the period. Finally, Private Capital Advisors Inc. boosted its stake in Celgene Corporation by 0.3% in the first quarter. Private Capital Advisors Inc. now owns 15,050 shares of the biopharmaceutical company’s stock valued at $1,873,000 after buying an additional 50 shares during the period. Institutional investors and hedge funds own 78.39% of the company’s stock.

Shares of Celgene Corporation (NASDAQ CELG) traded up 0.59% during mid-day trading on Friday, hitting $136.70. The company had a trading volume of 3,197,673 shares. The company has a market capitalization of $106.95 billion, a price-to-earnings ratio of 42.34 and a beta of 1.89. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The company has a 50-day moving average price of $132.00 and a 200-day moving average price of $123.32.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period last year, the firm earned $1.44 EPS. The company’s quarterly revenue was up 18.7% on a year-over-year basis. On average, equities analysts anticipate that Celgene Corporation will post $7.32 EPS for the current year.

WARNING: “Celgene Corporation (NASDAQ:CELG) Stake Held by Yorktown Management & Research Co Inc” was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://baseballnewssource.com/markets/celgene-corporation-nasdaqcelg-position-held-by-yorktown-management-research-co-inc-updated-updated-updated/1180050.html.

Several equities research analysts have weighed in on the company. Cann reiterated a “buy” rating and issued a $175.00 price objective on shares of Celgene Corporation in a report on Tuesday, August 1st. Jefferies Group LLC reiterated a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a report on Monday, July 31st. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 price objective (up previously from $148.00) on shares of Celgene Corporation in a report on Monday, July 31st. Argus upgraded Celgene Corporation from a “hold” rating to a “buy” rating and increased their price objective for the stock from $96.93 to $160.00 in a report on Monday, July 31st. Finally, Barclays PLC reiterated a “hold” rating and issued a $135.00 price objective on shares of Celgene Corporation in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have assigned a buy rating to the company. Celgene Corporation presently has a consensus rating of “Buy” and a consensus target price of $147.06.

In related news, Director James J. Loughlin sold 18,500 shares of the firm’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $133.57, for a total value of $2,471,045.00. Following the transaction, the director now directly owns 32,877 shares of the company’s stock, valued at approximately $4,391,380.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now directly owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The disclosure for this sale can be found here. Insiders have sold a total of 235,255 shares of company stock worth $31,377,042 over the last 90 days. Insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.